Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK MDM2 amp TP53 wild-type |
Therapy | Milademetan + Trametinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK MDM2 amp TP53 wild-type | lung adenocarcinoma | sensitive | Milademetan + Trametinib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Mekinist (trametinib) and Milademetan resulted in increased tumor growth inhibition compared to either therapy alone in a patient-derived xenograft model of lung adenocarcinoma harboring wild-type TP53, EML4-ALK, and MDM2 amplification (PMID: 37182602). | 37182602 |
PubMed Id | Reference Title | Details |
---|---|---|
(37182602) | Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. | Full reference... |